Drug Profile
Research programme: multiple sclerosis therapy - Salus Therapeutics
Alternative Names: Multiple sclerosis therapy research programme - Salus TherapeuticsLatest Information Update: 09 Mar 2015
Price :
$50
*
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 30 Aug 2001 Preclinical development for Multiple sclerosis in USA (Unknown route)